STAT+: ‘Missed opportunities’: Why a U.K. government plan to disclose financial ties between pharma and docs may fall short
The U.K. plans to create what resembles the OpenPayments database in the U.S., which emerged from scandals and probes into undue industry influence over physicians and researchers.
Earlier this month, the U.K. government issued a to gather information and opinions about payments that drug and device makers give to the medical community. The move came amid in the U.S., which emerged from scandals and probes into undue industry influence over physicians and researchers. The U.K. effort has been welcomed by industry critics, but one academic says there is reason for caution. Piotr Ozieranski, a reader at the University of Bath, who studies interactions between drug companies, the U.K. health service, and patient groups, says the proposal does not go far enough. We recently spoke with Ozieranski about the issue. This is an edited version of our conversation.
